Evidence map›Paper›PMID 42813504›Full record

ArticleClinical pharmacology and therapeutics2026

Targeting Problems and Adhering to Standards: A Pathway to Uniform Clinical Laboratory Processes that Maximize the Benefits of Pharmacogenomics.

Elizabeth Fieg, Ben Kerman, Lucas A Berenbrok, Samantha Frear, Lauren Marcath, Mylynda Massart, Natasha Berman

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elizabeth FiegBaylor Genetics, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9422-2373
Ben KermanDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0008-9402-2054
Lucas A BerenbrokDepartment of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-9479-8209
Samantha FrearDepartment of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts, USA.
Lauren MarcathBaylor Genetics, Houston, Texas, USA.
Mylynda MassartUPMC Primary Care Precision Medicine Clinic, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-8835-7957
Natasha BermanUPMC Primary Care Precision Medicine Clinic, Pittsburgh, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Commercial laboratories often have differing approaches to pharmacogenomic testing, which detects the presence of germline genetic variants associated with drug response. Setting standards for clinical laboratories and defining criteria for clinicians to consider when choosing a testing laboratory can help maximize the benefits of pharmacogenomics. Here, we propose specific laboratory practices that should be discontinued or established and followed as standard practice. We also propose ideal practices that would advance pharmacogenomics in clinical care.

Identifiers

PMID42813504
PMCPMC13625150

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.